Thanks to everyone who came out on Saturday, October 27th for Carbone’s Race for Research! Together, we raised more than $182K among the more than 1600 people who signed up to participate!
Cancer Center News
Spring 2018 Clinical Research Internship Program
The University of Wisconsin Carbone Cancer Center Clinical Research Internship program was brand new in the spring semester of 2018 and based on the idea of connecting students with clinical research through specific projects and …
Wisconsin Study Seeks ‘Extreme Survivors’ of Metastatic Breast Cancer
Some patients can live for years, and even decades, after breast cancer has spread to their bones and other tissues. A new international study is looking for patients with metastatic breast cancer in hopes of unlocking the …
Metastasis enablers: Findings could unlock new ovarian cancer treatments
UW Carbone Scientists to Present at Annual Cancer Research Conference
As cancer researchers from across the country descend on Chicago this week for the American Association of Cancer Research’s annual conference, University of Wisconsin Carbone Cancer Center faculty, staff and students are among them. All told, over 60 …
Dr. Rice on the Importance of Clinical Trials in Gynecologic Cancer
Laurel W. Rice, MD, chair, Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, discusses the importance of enrolling patients with gynecologic cancer on clinical trials. Without the ability for …
Long-term cancer survivor beats odds, prompts study
After her initial diagnosis in 1978, Peg Geisler’s cancer returned and spread to her bones in 1982. A doctor told her she had a 15 percent chance of living another five years. Her story inspired …
Fewer Recalls Associated with Higher Rates of Interval Breast Cancers
Lower screening mammography recall rates are associated with higher rates of breast cancers detected between screenings, or interval cancers, according to a new study in Radiology. Researchers analyzed 5,126,689 screening episodes, or the period during which …
Gynecologic Cancers Significantly Underfunded Compared with Other Cancers
In comparison to the funding and survival rate of many other cancer types, funding for ovarian, cervical, and uterine cancer does not align with their survival rates. This finding was presented at the Society of Gynecologic Oncology’s …
Neuroblastoma Treatment Granted Orphan Drug Designation
This morning, Cellectar Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CLR 131 for the treatment of neuroblastoma. CLR 131 is the company’s lead Phospholipid Drug Conjugate …